[Skip to Content]

Quiz

Venous Thromboembolism

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD ExacerbationA Randomized Clinical Trial

Educational Objective
To understand the benefits and risks of an active strategy for the detection of pulmonary embolism in patients hospitalized for an exacerbation of chronic obstructive pulmonary disease (COPD).

1 Credit CME

JAMA

Published Online: October 5, 2021

Original Investigation

Article Information and Disclosures

David Jiménez, MD, PhD^1,2,3;

Alvar Agustí, MD, PhD⁴;

Eva Tabernero, MD⁵;

et al

Luis Jara-Palomares, MD, PhD⁶;

Ascensión Hernando, MD, PhD⁷;

Pedro Ruiz-Artacho, MD, PhD^3,8;

Gregorio Pérez-Peñate, MD, PhD⁹;

Agustina Rivas-Guerrero, MD¹⁰;

María Jesús Rodríguez-Nieto, MD, PhD^3,11;

Aitor Ballaz, MD¹²;

Ramón Agüero, MD¹³;

Sonia Jiménez, MD¹⁴;

Myriam Calle-Rubio, MD, PhD¹⁵;

Raquel López-Reyes, MD¹⁶;

Pedro Marcos-Rodríguez, MD¹⁷;

Deisy Barrios, MD, PhD¹;

Carmen Rodríguez, MD¹;

Alfonso Muriel, PhD¹⁸;

Laurent Bertoletti, MD, PhD¹⁹;

Francis Couturaud, MD, PhD²⁰;

Menno Huisman, MD, PhD²¹;

José Luis Lobo, MD¹⁰;

Roger D. Yusen, MD²²;

Behnood Bikdeli, MD, MS^23,24,25;

Manuel Monreal, MD, PhD^3,26;

Remedios Otero, MD, PhD^3,6;

for the SLICE Trial Group

Author Affiliations

¹Respiratory Department, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain
²Medicine Department, Universidad de Alcalá, Madrid, Spain
³CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain
⁴Respiratory Institute, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain
⁵Respiratory Department, Hospital Universitario Cruces, Biocruces-Bizkaia, Barakaldo, Spain
⁶Respiratory Department, Virgen del Rocío Hospital and Instituto de Biomedicina, Sevilla
⁷Respiratory Department, Hospital Doce de Octubre, Madrid, Spain
⁸Department of Internal Medicine, Clínica Universidad de Navarra, Madrid; Interdisciplinar Teragnosis and Radiosomics Research Group (INTRA-Madrid), Universidad de Navarra, Madrid, Spain
⁹Respiratory Department and Pulmonary Vascular Unit, HUGC Dr. Negrín, Las Palmas GC, Spain
¹⁰Respiratory Department, Hospital Araba, Vitoria, Spain
¹¹Respiratory Department, Fundación Jiménez Díaz, Madrid, Spain
¹²Respiratory Department, Hospital Galdakao-Usansolo, Bilbao, Spain
¹³Respiratory Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
¹⁴Emergency Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
¹⁵Respiratory Department, Hospital Clínico San Carlos, Madrid; Medicine Department, Universidad Complutense, Madrid, Spain
¹⁶Respiratory Department, Hospital La Fe, Valencia, Spain
¹⁷Respiratory Department, Complejo Hospitalario Universitario de A Coruña (CHUAC), INIBIC, Universidade da Coruña, A Coruña, Spain
¹⁸Biostatistics Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, CIBERESP, Madrid, Spain
¹⁹CHU de St-Etienne, Service de Médecine Vasculaire et Thérapeutique; INSERM, UMR1059, Université Jean-Monnet; INSERM, CIC-1408, CHU de Saint-Etienne; INNOVTE, CHU de Saint-Etienne; all in F-42055, Saint-Etienne, France
²⁰Department of Internal Medicine and Chest Diseases, EA3878 (G.E.T.B.O.), CIC INSERM 0502, University Hospital of Brest, European University of Occidental Brittany, Brest, France
²¹Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
²²Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine in St Louis, St Louis, Missouri
²³Cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
²⁴Center for Outcomes Research and Evaluation (CORE), Yale University School of Medicine, New Haven, Connecticut
²⁵Cardiovascular Research Foundation, New York, New York
²⁶Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona; Universidad Católica de Murcia, Murcia, Spain

SLICE Trial Groupfor the

Read article on JAMA Network

Read Article Take Quiz

Key Points

Question Does an active search for pulmonary embolism (PE) improve outcomes in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD)?

Findings This multicenter randomized clinical trial included 746 patients who required hospitalization for exacerbation of COPD and were randomized to receive usual care plus an active strategy for diagnosing PE or usual care alone. The primary outcome (a composite of nonfatal symptomatic venous thromboembolism, readmission for COPD, or death within 90 days after randomization) occurred in 29.7% of patients in the intervention group vs 29.2% in the control group, a difference that was not statistically significant.

Meaning Among patients hospitalized for an exacerbation of COPD, addition of an active diagnostic strategy for PE to usual care compared with usual care alone did not improve a composite set of health outcomes.

Abstract

Importance Active search for pulmonary embolism (PE) may improve outcomes in patients hospitalized for exacerbations of chronic obstructive pulmonary disease (COPD).

Objective To compare usual care plus an active strategy for diagnosing PE with usual care alone in patients hospitalized for COPD exacerbation.

Design, Setting, and Participants Randomized clinical trial conducted across 18 hospitals in Spain. A total of 746 patients were randomized from September 2014 to July 2020 (final follow-up was November 2020).

Interventions Usual care plus an active strategy for diagnosing PE (D-dimer testing and, if positive, computed tomography pulmonary angiogram) (n = 370) vs usual care (n = 367).

Main Outcomes and Measures The primary outcome was a composite of nonfatal symptomatic venous thromboembolism (VTE), readmission for COPD, or death within 90 days after randomization. There were 4 secondary outcomes, including nonfatal new or recurrent VTE, readmission for COPD, and death from any cause within 90 days. Adverse events were also collected.

Results Among the 746 patients who were randomized, 737 (98.8%) completed the trial (mean age, 70 years; 195 [26%] women). The primary outcome occurred in 110 patients (29.7%) in the intervention group and 107 patients (29.2%) in the control group (absolute risk difference, 0.5% [95% CI, −6.2% to 7.3%]; relative risk, 1.02 [95% CI, 0.82-1.28]; P = .86). Nonfatal new or recurrent VTE was not significantly different in the 2 groups (0.5% vs 2.5%; risk difference, −2.0% [95% CI, −4.3% to 0.1%]). By day 90, a total of 94 patients (25.4%) in the intervention group and 84 (22.9%) in the control group had been readmitted for exacerbation of COPD (risk difference, 2.5% [95% CI, −3.9% to 8.9%]). Death from any cause occurred in 23 patients (6.2%) in the intervention group and 29 (7.9%) in the control group (risk difference, −1.7% [95% CI, −5.7% to 2.3%]). Major bleeding occurred in 3 patients (0.8%) in the intervention group and 3 patients (0.8%) in the control group (risk difference, 0% [95% CI, −1.9% to 1.8%]; P = .99).

Conclusions and Relevance Among patients hospitalized for an exacerbation of COPD, the addition of an active strategy for the diagnosis of PE to usual care, compared with usual care alone, did not significantly improve a composite health outcome. The study may not have had adequate power to assess individual components of the composite outcome.

Trial Registration ClinicalTrials.gov Identifier: NCT02238639

Take Quiz

Buy This Activity

Article Information

Corresponding Author: David Jiménez, MD, PhD, Respiratory Department and Medicine Department, Ramón y Cajal Hospital, IRYCIS and Alcalá University, CIBER Enfermedades Respiratorias (CIBERES), Colmenar Rd, Km. 9,100, 28034 Madrid, Spain (djimenez.hrc@gmail.com).

Accepted for Publication: August 16, 2021.

Author Contributions: Dr D. Jiménez had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: D. Jimenez, Calle Rubio, Rodriguez, Bertoletti, Yusen, Monreal, Otero.

Acquisition, analysis, or interpretation of data: D. Jimenez, Agusti, Tabernero, Jara-Palomares, Hernando, Ruiz-Artacho, Perez-Peñate, Rivas-Guerrero, Rodriguez Nieto, Ballaz, Aguero, S. Jimenez, Calle Rubio, Lopez-Reyes, Marcos, Barrios, Muriel, Bertoletti, Couturaud, Huisman, Lobo, Yusen, Bikdeli, Monreal, Otero.

Drafting of the manuscript: D. Jimenez, Agusti, Marcos, Barrios, Rodriguez.

Critical revision of the manuscript for important intellectual content: D. Jimenez, Agusti, Tabernero, Jara-Palomares, Hernando, Ruiz-Artacho, Perez-Peñate, Rivas-Guerrero, Rodriguez Nieto, Ballaz, Aguero, S. Jimenez, Calle Rubio, Lopez-Reyes, Marcos, Muriel, Bertoletti, Couturaud, Huisman, Lobo, Yusen, Bikdeli, Monreal, Otero.

Statistical analysis: D. Jimenez, Marcos, Muriel, Yusen.

Obtained funding: D. Jimenez, Jara-Palomares, Barrios, Otero.

Administrative, technical, or material support: D. Jimenez, Perez-Peñate, Lopez-Reyes, Marcos.

Supervision: D. Jimenez, Agusti, Rivas-Guerrero, Calle Rubio, Marcos, Bertoletti, Huisman, Monreal, Otero.

Conflict of Interest Disclosures: Dr D. Jimenez reported receiving personal fees from Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Leo Pharma, and Pfizer and grants from Daiichi Sankyo, Rovi, and Sanofi outside the submitted work. Dr Agusti reported receiving grants and personal fees from AstraZeneca, GlaxoSmithKline, and Menarini and personal fees from Chiesi outside the submitted work. Dr Jara-Palomares reported receiving grants from Leo Pharma and MSD and personal fees from Daichii, Rovi, GlaxoSmithKline, and Actellion outside the submitted work. Dr Ruiz-Artacho reported receiving personal fees from Bristol Myers Squibb, Leo Pharma, and Daiichi Sankyo and grants from ROVI outside the submitted work. Dr Calle Rubio reported receiving personal fees from Boehringer Ingelheim, AstraZeneca, Menarini, Novartis, Grifols, and GlaxoSmithKline and consulting fees from GlaxoSmithKline, Gebro Pharma, and Novartis during the conduct of the study. Dr Bertoletti reported receiving personal fees from board, symposia, and congress travel from Actelion, Aspen, Bayer, Bristol Myers Squibb/Pfizer, Leo Pharma, and MSD and travel support from Daiichi Sankyo outside the submitted work. Dr Couturaud reported receiving grants from Bristol Myers Squibb; personal fees from Bayer, AstraZeneca, and Bristol Myers Squibb; and travel support from Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, InterMune, and Actelion outside the submitted work. Dr Huisman reported receiving grants from Pfizer-Bristol Myers Squibb Alliance, Bayer Health Care, ZonMw, the Dutch Heart Foundation outside the submitted work. Dr Yusen reported receiving personal fees from Ortho Pharmaceuticals for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Organon for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Merck for providing expert review of venous thromboembolism cases and relationship to hormonal contraceptive therapy, Portola for providing consulting related to the oral anticoagulant betrixaban, and Janssen for providing consulting related to the oral anticoagulant rivaroxaban and grants from Cyclomedica for funding as a co-investigator of a study of an imaging agent, Technegas, outside the submitted work. Dr Bikdeli reported being a consulting expert, on behalf of the plaintiff, for litigation related to 2 specific brand models of inferior vena cava filters. Dr Monreal reported receiving educational grants from Sanofi and Rovi Pharmaceuticals for research and personal fees from Sanofi and Leo Pharma for advisory committees outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by grants from the Instituto de Salud Carlos III (PI14/00400), Chest Foundation, Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Neumosur, and Daiichi Sankyo.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: A listing of the SLICE investigators appears in Supplement 4.

Additional Contributions: We express our gratitude to S&H Medical Science Service for their quality control data, logistic, and administrative support.

References

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2020. Accessed January 10, 2021. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf

Miravitlles M , Soler-Cataluña JJ , Calle M , et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017: pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324-335. doi:10.1016/j.arbres.2017.03.018 PubMed Google Scholar Crossref

Pauwels RA , Buist AS , Calverley PM , Jenkins CR , Hurd SS ; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276. doi:10.1164/ajrccm.163.5.2101039 PubMed Google Scholar Crossref

Vestbo J , Hurd SS , Agustí AG , et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-365. doi:10.1164/rccm.201204-0596PP PubMed Google Scholar Crossref

Wedzicha JA , Seemungal TA . COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786-796. doi:10.1016/S0140-6736(07)61382-8 PubMed Google Scholar Crossref

Papi A , Bellettato CM , Braccioni F , et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-1121. doi:10.1164/rccm.200506-859OC PubMed Google Scholar Crossref

Beghé B , Verduri A , Roca M , Fabbri LM . Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J. 2013;41(4):993-995. doi:10.1183/09031936.00180812 PubMed Google Scholar Crossref

Winter JH , Buckler PW , Bautista AP , et al. Frequency of venous thrombosis in patients with an exacerbation of chronic obstructive lung disease. Thorax. 1983;38(8):605-608. doi:10.1136/thx.38.8.605 PubMed Google Scholar Crossref

Tillie-Leblond I , Marquette CH , Perez T , et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006;144(6):390-396. doi:10.7326/0003-4819-144-6-200603210-00005 PubMed Google Scholar Crossref

10.

Rutschmann OT , Cornuz J , Poletti PA , et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? Thorax. 2007;62(2):121-125. doi:10.1136/thx.2006.065557 PubMed Google Scholar Crossref

11.

Rizkallah J , Man SFP , Sin DD . Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135(3):786-793. doi:10.1378/chest.08-1516 PubMed Google Scholar Crossref

12.

Kline JA , Garrett JS , Sarmiento EJ , Strachan CC , Courtney DM . Over-testing for suspected pulmonary embolism in American emergency departments: the continuing epidemic. Circ Cardiovasc Qual Outcomes. 2020;13(1):e005753. doi:10.1161/CIRCOUTCOMES.119.005753 PubMed Google Scholar

13.

Nijkeuter M , Söhne M , Tick LW , et al; Christopher Study Investigators. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. Chest. 2007;131(2):517-523. doi:10.1378/chest.05-2799 PubMed Google Scholar Crossref

14.

Anderson DR , Kahn SR , Rodger MA , et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007;298(23):2743-2753. doi:10.1001/jama.298.23.2743 PubMed Google Scholar Crossref

15.

Jiménez D , Agustí A , Monreal M , et al; SLICE investigators. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clin Cardiol. 2019;42(3):346-351. doi:10.1002/clc.23161 PubMed Google Scholar Crossref

16.

Kaatz S , Ahmad D , Spyropoulos AC , Schulman S ; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119-2126. doi:10.1111/jth.13140 PubMed Google Scholar Crossref

17.

Aleva FE , Voets LWLM , Simons SO , de Mast Q , van der Ven AJAM , Heijdra YF . Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and meta-analysis. Chest. 2017;151(3):544-554. doi:10.1016/j.chest.2016.07.034 PubMed Google Scholar Crossref

18.

Pozo-Rodríguez F , López-Campos JL , Alvarez-Martínez CJ , et al; AUDIPOC Study Group. Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study. PLoS One. 2012;7(7):e42156. doi:10.1371/journal.pone.0042156 PubMed Google Scholar

19.

Couturaud F , Bertoletti L , Pastre J , et al; PEP Investigators. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms. JAMA. 2021;325(1):59-68. doi:10.1001/jama.2020.23567 PubMed Google Scholar Crossref

20.

Kearon C , de Wit K , Parpia S , et al; PEGeD Study Investigators. Diagnosis of pulmonary embolism with D-dimer adjusted to clinical probability. N Engl J Med. 2019;381(22):2125-2134. doi:10.1056/NEJMoa1909159 PubMed Google Scholar Crossref

21.

Righini M , Van Es J , Den Exter PL , et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117-1124. doi:10.1001/jama.2014.2135 PubMed Google Scholar Crossref

22.

Robert-Ebadi H , Robin P , Hugli O , et al. Impact of age-adjusted D-dimer cutoff to exclude pulmonary embolism: a multinational prospective real-life study (the RELAX-PE study). Circulation. 2021;143(18):1828-1830. doi:10.1161/CIRCULATIONAHA.120.052780 PubMed Google Scholar Crossref

23.

Bertoletti L , Quenet S , Mismetti P , et al; RIETE Investigators. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J. 2012;39(4):862-868. doi:10.1183/09031936.00058811 PubMed Google Scholar Crossref

24.

Eichinger S , Weltermann A , Minar E , et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med. 2004;164(1):92-96. doi:10.1001/archinte.164.1.92 PubMed Google Scholar Crossref

25.

van Es J , Douma RA , Schreuder SM , et al. Clinical impact of findings supporting an alternative diagnosis on CT pulmonary angiography in patients with suspected pulmonary embolism. Chest. 2013;144(6):1893-1899. doi:10.1378/chest.13-0157 PubMed Google Scholar Crossref

26.

Beyer-Westendorf J , Büller H . External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost. 2011;9(11):2153-2158. doi:10.1111/j.1538-7836.2011.04507.x PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD ExacerbationA Randomized Clinical Trial

Discriminative Accuracy of COPD Screening Instruments in Low- and Middle-Income Countries

A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation—Reply

A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation

Review of Acute Pulmonary Embolism

See More

AMA CME Accreditation Information

Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD ExacerbationA Randomized Clinical Trial

Discriminative Accuracy of COPD Screening Instruments in Low- and Middle-Income Countries

A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation—Reply

A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation

Review of Acute Pulmonary Embolism

See More

See More About

AMA CME Accreditation Information

Want full access to the AMA Ed Hub?

AMA Membership provides:

Sign in to access

Want full access to the AMA Ed Hub?

Sign in to customize your interests

With a personal account, you can:

Name Your Search

Sign in to save your search

With a personal account, you can:

Lookup An Activity

My Saved Searches

My Saved Courses

Purchase access